{"id":63900,"date":"2026-06-28T17:38:17","date_gmt":"2026-06-28T21:38:17","guid":{"rendered":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/astrazeneca-reports-positive-rare-disease-trial-results-amid-uk-defense-spending-concerns\/63900\/"},"modified":"2026-06-28T17:38:17","modified_gmt":"2026-06-28T21:38:17","slug":"astrazeneca-reports-positive-rare-disease-trial-results-amid-uk-defense-spending-concerns","status":"publish","type":"post","link":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/astrazeneca-reports-positive-rare-disease-trial-results-amid-uk-defense-spending-concerns\/63900\/","title":{"rendered":"AstraZeneca Reports Positive Rare Disease Trial Results Amid UK Defense Spending Concerns"},"content":{"rendered":"<h2>Key Takeaways<\/h2>\n<ul>\n<li><strong>AstraZeneca (<a href=\"\/stock\/AZN\">AZN<\/a>)<\/strong> announced positive <strong>Phase III<\/strong> results for <strong>efzimfotase alfa (ALXN1850)<\/strong>, achieving a median <strong>RGI-C score of 1.67<\/strong> versus <strong>0.00<\/strong> for placebo in pediatric patients with hypophosphatasia (HPP).<\/li>\n<li>The <strong>White House<\/strong> expressed concern that the <strong>United Kingdom<\/strong> may fail to honor its pledge to raise defense spending to <strong>5% of GDP<\/strong>, warning of potential &quot;false promises&quot; made to satisfy the <strong>Trump administration<\/strong>.<\/li>\n<li>Incoming Prime Minister <strong>Andy Burnham<\/strong> is expected to postpone setting a firm date for reaching a <strong>3% GDP<\/strong> defense spending target in an upcoming government plan, despite signaling broad support for the military.<\/li>\n<li><strong>AstraZeneca (<a href=\"\/stock\/AZN\">AZN<\/a>)<\/strong> estimates peak annual sales for its new HPP therapy could reach between <strong>$3 billion and $5 billion<\/strong>, significantly higher than the <strong>$1.7 billion<\/strong> generated by its predecessor, <strong>Strensiq<\/strong>.<\/li>\n<\/ul>\n<h2>AstraZeneca Achieves Clinical Milestone in Rare Bone Disease<\/h2>\n<p><strong>AstraZeneca (<a href=\"\/stock\/AZN\">AZN<\/a>)<\/strong> and its rare disease unit, <strong>Alexion<\/strong>, reported successful outcomes from the <strong>MULBERRY Phase III<\/strong> trial evaluating <strong>efzimfotase alfa (ALXN1850)<\/strong>. The investigational enzyme replacement therapy demonstrated a statistically significant improvement in bone health for children aged 2 to 12 with <strong>hypophosphatasia (HPP)<\/strong>.<\/p>\n<p>The study met its primary endpoint with a median <strong>Radiographic Global Impression of Change (RGI-C)<\/strong> score of <strong>1.67<\/strong> compared to <strong>0.00<\/strong> for the placebo group at week 25. Furthermore, the trial achieved a key secondary endpoint in <strong>bone health<\/strong> as measured by the <strong>Rickets Severity Score (RSS)<\/strong>, showing a median difference of <strong>-1.00<\/strong> against placebo. These results support the potential for a self-administered treatment taken every two weeks, offering a more convenient dosing schedule than current therapies.<\/p>\n<h2>Transatlantic Tensions Rise Over UK Defense Commitments<\/h2>\n<p>The <strong>White House<\/strong> has signaled growing skepticism regarding the <strong>United Kingdom&#39;s<\/strong> ability to deliver on a high-profile pledge to increase defense expenditures to <strong>5% of GDP<\/strong>. According to reports from <em>The Telegraph<\/em>, U.S. officials are concerned that some European allies may have made &quot;false promises&quot; to appease <strong>President Donald Trump<\/strong> during recent negotiations.<\/p>\n<p>The <strong>5% target<\/strong>\u2014composed of <strong>3.5% for core defense<\/strong> and <strong>1.5% for resilience<\/strong>\u2014was established under pressure to increase burden-sharing within <strong>NATO<\/strong>. U.S. administration officials are reportedly reviewing the American military footprint in Europe, suggesting that assets could be relocated if allies do not meet these aggressive rearmament goals.<\/p>\n<h2>Political Transition in UK Impacts Defense Strategy<\/h2>\n<p>Concerns are mounting as <strong>Andy Burnham<\/strong> prepares to succeed <strong>Keir Starmer<\/strong> as Prime Minister. While <strong>Burnham<\/strong> has indicated support for elevated military funding, the upcoming government defense plan is expected to avoid committing to a specific timeline for reaching <strong>3% of GDP<\/strong> in spending.<\/p>\n<p>This expected postponement has drawn criticism from defense advocates who argue that a lack of a clear trajectory undermines the UK&#39;s standing within <strong>NATO<\/strong>. The delay comes amid significant fiscal constraints and internal political pressure to prioritize social spending over military expansion, potentially complicating the UK&#39;s relationship with the <strong>Trump administration<\/strong> ahead of the upcoming <strong>NATO summit<\/strong> in Ankara.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key Takeaways AstraZeneca (AZN) announced positive Phase III results for efzimfotase alfa (ALXN1850), achieving a median RGI-C score of 1.67 [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":50383,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"rank_math_schema_Article":[],"rank_math_focus_keyword":[],"rank_math_description":[],"financial_data_references":[],"stock_symbols_mentioned":[],"footnotes":""},"categories":[5012],"tags":[647,4810,5041,5046,5248,6253,19769,19770,19771],"class_list":["post-63900","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-breaking-news","tag-azn","tag-trump-administration","tag-nato","tag-defense-spending","tag-uk-politics","tag-astrazeneca","tag-alxn1850","tag-hpp","tag-rss"],"_links":{"self":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/63900","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/comments?post=63900"}],"version-history":[{"count":0,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/63900\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media\/50383"}],"wp:attachment":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media?parent=63900"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/categories?post=63900"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/tags?post=63900"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}